vimarsana.com

Page 3 - லெவின் புற்றுநோய் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma

Eighteen-month follow-up data from pivotal CARTITUDE-1 study, including progression-free-survival data, to be presented at ASCO and EHA Annual Meetings Findings from the Phase 2 CARTITUDE-2 study

United statesCiltacabtagene autoleucelNoah reymondJennifer mcintyreSaadz usmaniChristopher deloreficeSen zhuangEdmond chanHematology am soc hematol educ programNational cancer instituteJanssen biotech incAmerican society of clinical oncologyAmerican society of hematology annual meetingEuropean hematology associationJanssen research developmentCongress abstract

City of Hope Orange County s Dr Kim named among the nation s top science and policy leaders

Preeminent oncologist Edward S. Kim, M.D., M.B.A., Physician-in-Chief, City of Hope Orange County and Vice Physician-in-Chief, City of

North carolinaUnited statesOrange countyEdwards kimEllenv sigalEd kimCity of hope national medical centerAtrium health in charlotteAmerican society of clinical oncologyUniversity of texas md anderson cancer centerLevine cancer instituteFriends of cancer researchHope orangeHope orange countyVice physician in chiefHope national medical center

FDA approves new imaging tool to find advanced prostate cancer

The approach won't replace traditional blood screening tests, but it could help guide doctors when cancer spreads.

New yorkUnited statesMemorial sloan kettering cancer centerNorth carolinaDana farber cancer instituteSan franciscoMichael morrisLos angelesXiao weiDerek raghavanThomas hopeJustin greggUniversity of californiaDepartment of radiologyDrug administrationMd anderson cancer center

FDA approves new imaging tool to find advanced prostate cancer, drugmaker says

FDA approves new imaging tool to find advanced prostate cancer, drugmaker says TODAY 2 hrs ago © Provided by TODAY The Food and Drug Administration has approved a new imaging agent to detect prostate cancer after it has spread to other parts of the body, the company that makes the agent said Thursday. Experts say the tracer, made by medical imaging company Lantheus, will give doctors an important visual aid to guide them to metastatic prostate cancer cells that, before now, were difficult to spot. Prostate cancer is the second leading cause of cancer deaths in men in the United States, after lung cancer, according to the American Cancer Society. More than 34,000 men die of the disease every year.

New yorkUnited statesMemorial sloan kettering cancer centerNorth carolinaDana farber cancer instituteSan franciscoMichael morrisLos angelesXiao weiDerek raghavanThomas hopeJustin greggUniversity of californiaDepartment of radiologyDrug administrationMd anderson cancer center

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021

Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 19, 2021 /PRNewswire/ Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced additional data from the Company s dose-escalation cohort of the Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) for patients with advanced, progressive ovarian cancer; the data will also be presented as a poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting to be held on June 4-8, 2021.

United statesSutro biopharmaMaggie bellerAnniej changArturo molinaR wendel naumannSutro xpressAmerican society of clinical oncologyCelgene corporationCompany corporate presentationAtrium healthExchange commissionMerck kgaGynecologic oncology research at levine cancer instituteSutro biopharma incMerck kgaa

vimarsana © 2020. All Rights Reserved.